Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

kalceks jsc - atracurium (atracurium besylate) - solution for injection/infusion - 10mg/ml

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

kalceks jsc - atracurium (atracurium besylate) - solution for injection/infusion - 10mg/ml

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - atracurium besilate 10 mg/ml - solution for injection - 10 mg/ml - active: atracurium besilate 10 mg/ml excipient: benzenesulfonic acid water for injection - dbl™ atracurium besylate injection is indicated as an adjunct to general anaesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation.

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

kalceks jsc - atracurium (atracurium besylate) - solution for injection/infusion - 10mg/ml

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

kalceks jsc - atracurium (atracurium besylate) - solution for injection/infusion - 10mg/ml

Jordan - English - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

مستودع أدوية أبو شريف - abu sharef medical stores - atracurium besylate 10 mg/ml - 10 mg/ml

United States - English - NLM (National Library of Medicine)

hospira, inc. - atracurium besylate (unii: 40ax66p76p) (atracurium - unii:2gq1iry63p) - atracurium besylate 10 mg in 1 ml - atracurium besylate injection is indicated, as an adjunct to general anesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation. atracurium besylate is contraindicated in patients known to have a hypersensitivity to it. use of atracurium besylate from multiple dose vials containing benzyl alcohol as a preservative is contraindicated in patients with a known hypersensitivity to benzyl alcohol.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - atracurium besilate, quantity: 50 mg - injection - excipient ingredients: benzenesulfonic acid; water for injections - atracurium besylate injection is indicated as an adjunct to general anaesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation.

United States - English - NLM (National Library of Medicine)

jiangsu hengrui medicine co., ltd. - cisatracurium besylate (unii: 80ys8o1mbs) (cisatracurium - unii:qx62kli41n) - cisatracurium 2 mg in 1 ml - cisatracurium besylate injection is indicated: - as an adjunct to general anesthesia to facilitate tracheal intubation in adults and in pediatric patients 1 month to 12 years of age - to provide skeletal muscle relaxation in adults during surgical procedures or during mechanical ventilation in the icu - to provide skeletal muscle relaxation during surgical procedures via infusion in pediatric patients 2 years and older limitations of use cisatracurium besylate injection is not recommended for rapid sequence endotracheal intubation due to the time required for its onset of action. cisatracurium besylate injection is contraindicated in patients with known hypersensitivity to cisatracurium. severe anaphylactic reactions to cisatracurium have been reported [see warnings and precautions ( 5.4)] . the use of 10 ml cisatracurium multiple-dose vials is contraindicated for use in pediatric patients less than 1 month of age and low birth-weight infants because the formulation contains benzyl alcohol [see warnings and

United States - English - NLM (National Library of Medicine)

jiangsu hengrui medicine co., ltd. - cisatracurium besylate (unii: 80ys8o1mbs) (cisatracurium - unii:qx62kli41n) - cisatracurium 2 mg in 1 ml - cisatracurium besylate injection is indicated: - as an adjunct to general anesthesia to facilitate tracheal intubation in adults and in pediatric patients 1 month to 12 years of age - to provide skeletal muscle relaxation in adults during surgical procedures or during mechanical ventilation in the icu - to provide skeletal muscle relaxation during surgical procedures via infusion in pediatric patients 2 years and older limitations of use cisatracurium besylate injection is not recommended for rapid sequence endotracheal intubation due to the time required for its onset of action. cisatracurium besylate injection is contraindicated in patients with known hypersensitivity to cisatracurium. severe anaphylactic reactions to cisatracurium have been reported [see warnings and precautions ( 5.4)] . the use of 10 ml cisatracurium multiple-dose vials is contraindicated for use in pediatric patients less than 1 month of age and low birth-weight infants because the formulation contains benzyl alcohol [see warnings and